Welcome to our dedicated page for Tharimmune news (Ticker: THAR), a resource for investors and traders seeking the latest updates and insights on Tharimmune stock.
Tharimmune, Inc. (NASDAQ: THAR) generates news across two distinct but connected areas: clinical-stage biotechnology and digital asset treasury activities centered on Canton Coin and the Canton Network. Company press releases highlight progress for its lead asset TH104, an investigational nalmefene buccal film being advanced via a 505(b)(2) NDA pathway as a prophylactic countermeasure against respiratory and nervous system depression from high-potency opioids in military personnel and chemical incident responders.
News coverage frequently includes regulatory milestones such as positive feedback from the U.S. Food and Drug Administration (FDA) on Tharimmune’s pharmacokinetic modeling plan for TH104 and confirmation that no additional clinical trials appear necessary for a specified indication. Updates also address intellectual property developments, including patents granted or allowed in multiple countries for the TH104 transmucosal film technology, and corporate developments such as board appointments and leadership changes aligned with the company’s national security and addiction-related focus.
Tharimmune also issues news about its broader pipeline, including TH023, a novel oral monoclonal antibody program targeting TNF-alpha, and an early-stage multispecific biologic platform using its proprietary EpiClick™ Technology for solid tumors. These releases describe preclinical data, planned development steps, and strategic licensing arrangements.
On the digital asset side, Tharimmune’s news flow covers private placements, securities purchase agreements, and treasury strategy updates related to Canton Coin. The company reports on transactions led by institutional investors, its intention to operate as a Super Validator on the Canton Network, and commentary on initiatives such as the tokenization of U.S. Treasury securities on that network. Investors following THAR news can therefore expect a mix of clinical, regulatory, intellectual property, governance, financing, and blockchain-related announcements. Bookmarking this page provides a single stream of these updates as they are released.
Tharimmune (NASDAQ:THAR) will rebrand as Canton Strategic Holdings, Inc. and begin trading under ticker CNTN on February 18, 2026. The company pursues a digital asset treasury strategy after a $545 million private placement and a $55 million registered offering to fund Canton Coin, Super Validator operations, and ecosystem investments.
Key milestones include Super Validator approval, board additions, and commitment to quarterly ecosystem reporting to support institutional Canton Network adoption.
Tharimmune (NASDAQ: THAR) announced leadership changes effective Feb 5, 2026: Mark Wendland was elected Chairman of the Board and Angela Radkowski was named Chief Operating Officer. Vincent LoPriore will transition from Chairman to a Board member. Radkowski joins from DRW and Citadel and will lead operations, the Canton Network quarterly research initiative, and Super Validator activation. Tharimmune reaffirmed its Canton Network-aligned digital asset treasury strategy established in November 2025, plans CC acquisition, Super Validator operations, and investments in Canton-based applications. Tharimmune is the first publicly traded company supported by the Canton Foundation.
Tradeweb (Nasdaq: TW) reported 4Q25 revenue of $521.2M (up 12.5%) and ADV of $2.8T (up 23.3%). 4Q25 net income was $367.1M (up 129.5%), including $205.4M of non-operating gains on Canton Coin. The company raised its quarterly cash dividend to $0.14 (+16.7%) and authorized a $500M share repurchase program.
Tharimmune (NASDAQ: THAR) elected Jill Sommers and William Wiley, CFA to its Board of Directors, effective February 1, 2026. Both bring regulatory and capital‑markets leadership to support Tharimmune's Canton Network strategy, launched in November 2025, including CC acquisition and Super Validator operations.
The appointments aim to strengthen governance as the company advances institutional adoption of blockchain-enabled market infrastructure.
Tharimmune (NASDAQ: THAR) was approved on Jan 26, 2026 to operate a Super Validator on the Canton Network, allowing it to help secure transactions and accrue Canton Coin (CC) rewards to bolster its digital asset treasury. Tharimmune will publish quarterly research on onchain analytics, governance, tokenomics and roadmap updates, and will host quarterly public webinars to engage ecosystem participants. The announcement notes Super Validators support >700,000 daily transactions and $9 trillion in monthly transaction volume on the Canton Network. Tharimmune established its digital asset treasury strategy in November 2025 and plans to acquire CC and invest in Canton-based applications to drive institutional adoption. Tharimmune is identified as the first publicly traded company supported by the Canton Foundation.
Tharimmune (NASDAQ: THAR) announced closing of an underwritten registered direct offering on Jan 22, 2026 that issued 1,800,000 common shares at $2.92 per share and pre-funded warrants to purchase up to 17,000,000 shares at $2.9199 each. Gross proceeds to the company are approximately $55 million before underwriting discounts, commissions and offering expenses. Proceeds are earmarked for expansion of its Canton-centric digital asset treasury strategy and general corporate working capital. Clear Street acted as sole bookrunning manager; the offering relied on a shelf registration effective Jan 16, 2026 and a prospectus supplement filed Jan 20, 2026.
Tharimmune (NASDAQ: THAR) priced a $55.0 million underwritten registered offering on January 20, 2026, expected to close on or about January 21, 2026 subject to customary closing conditions.
The transaction includes issuance of 1,800,000 common shares at $2.92 per share and pre-funded warrants to purchase up to 17,000,000 common shares at $2.9199 per pre-funded warrant. Clear Street is sole bookrunner.
The offering is intended to provide additional growth capital for expansion of the company’s Canton-centric digital asset treasury strategy and working capital for general corporate purposes. The company filed a shelf registration (File No. 333-292648) with the SEC on January 9, 2026, which became effective January 16, 2026.
Tharimmune (NASDAQ: THAR) commented on the DTCC and Digital Asset partnership to tokenize U.S. Treasury securities on the Canton Network announced December 18, 2025. The company highlighted that DTCC custody covers ~$30 trillion in U.S. Treasuries and noted Canton Network's $9 trillion monthly transaction volume and >700,000 daily transactions as validation of institutional blockchain adoption.
Tharimmune said it established a digital asset treasury strategy in November 2025 with a $545 million private placement, has acquired Canton Coin, and is pursuing roles as a Super Validator and application investor to support Canton Network expansion.
Tharimmune (NASDAQ: THAR) appointed Jacob Asbury as Chief Financial Officer, effective December 12, 2025. Mr. Asbury will oversee capital planning, treasury management, financial reporting, and expansion of Tharimmune’s Canton Coin (CC) treasury infrastructure.
The company said Asbury brings nearly two decades of experience, including prior CFO roles at Clear Street Group, Performance Flight & Custom Jet Charters, and Instinet, and holds a B.S. from the University of Vermont. Tharimmune established its differentiated digital asset treasury (DAT) strategy in November 2025 and is applying to operate as a Super Validator while investing in Canton Network applications. Tharimmune is the first publicly traded company to leverage CC and is supported by the Canton Foundation.
Tharimmune (Nasdaq: THAR) received positive FDA feedback on its TH104 (nalmefene buccal film) pharmacokinetic simulation modeling plan following a Type D meeting on Nov 13, 2025. The FDA concurred with the proposed modeling approach and gave technical guidance to incorporate into the final plan, supporting the company's pathway toward a 505(b)(2) NDA. Tharimmune is also initiating a CMC plan to scale production and ensure product quality for advanced development.
PK simulations projected a ~30-minute onset to target concentration and ~24-hour sustained protective levels versus current naloxone effects of 30–90 minutes.